Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) SVP Richard J. Kim Sells 89 Shares
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) SVP Richard J. Kim sold 89 shares of Intercept Pharmaceuticals stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $128.64, for a total value of $11,448.96. Following the completion of the sale, the senior vice president now directly owns 11,253 shares of the company’s stock, valued at approximately $1,447,585.92. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Intercept Pharmaceuticals, Inc. (ICPT) traded down 0.40% during midday trading on Tuesday, reaching $124.50. The company had a trading volume of 359,270 shares. The firm’s 50 day moving average price is $119.14 and its 200-day moving average price is $115.33. Intercept Pharmaceuticals, Inc. has a 1-year low of $96.63 and a 1-year high of $177.93. The stock’s market capitalization is $3.11 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($3.61) EPS for the quarter, topping the consensus estimate of ($4.27) by $0.66. The company had revenue of $21 million for the quarter, compared to the consensus estimate of $15.88 million. Intercept Pharmaceuticals had a negative return on equity of 116.30% and a negative net margin of 825.58%. Intercept Pharmaceuticals’s quarterly revenue was up 4566.7% on a year-over-year basis. During the same period last year, the business posted ($5.17) EPS. Equities research analysts expect that Intercept Pharmaceuticals, Inc. will post ($14.40) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/18/intercept-pharmaceuticals-inc-nasdaqicpt-svp-richard-j-kim-sells-89-shares.html.
Several hedge funds and other institutional investors have recently made changes to their positions in ICPT. Norges Bank bought a new position in shares of Intercept Pharmaceuticals during the fourth quarter worth about $17,652,000. MARSHALL WACE ASIA Ltd bought a new position in shares of Intercept Pharmaceuticals during the first quarter worth about $13,012,000. Marshall Wace North America L.P. bought a new position in shares of Intercept Pharmaceuticals during the first quarter worth about $13,012,000. Macquarie Group Ltd. increased its position in shares of Intercept Pharmaceuticals by 54.2% in the first quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock worth $27,321,000 after buying an additional 84,954 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Intercept Pharmaceuticals by 4.7% in the first quarter. Vanguard Group Inc. now owns 1,270,984 shares of the biopharmaceutical company’s stock worth $143,749,000 after buying an additional 56,952 shares in the last quarter. Institutional investors and hedge funds own 84.25% of the company’s stock.
ICPT has been the subject of several analyst reports. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, March 22nd. Cowen and Company restated a “buy” rating and issued a $225.00 target price on shares of Intercept Pharmaceuticals in a research note on Monday, April 24th. Zacks Investment Research downgraded Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. Cantor Fitzgerald set a $60.00 target price on Intercept Pharmaceuticals and gave the stock a “sell” rating in a research note on Thursday, May 4th. Finally, Laidlaw upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 target price for the company in a research note on Friday, May 5th. Three analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $195.75.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.